Evidence map›Paper›PMID 31993839›Full record

ArticleEuropean radiology experimental2020

A machine learning approach for differentiating malignant from benign enhancing foci on breast MRI.

Natascha C D'Amico, Enzo Grossi, Giovanni Valbusa, Francesca Rigiroli, Bernardo Colombo, Massimo Buscema, Deborah Fazzini, Marco Ali, Ala Malasevschi, Gianpaolo Cornalba and 1 more

Abstract read
In one paragraph

Article in European radiology experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natascha C D'AmicoUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy. nataschaclaudia.damico@cdi.it.ORCID 0000-0002-9458-243X
Enzo GrossiBracco Imaging S.p.A., Via Egidio Folli 50, 20134, Milan, Italy.
Giovanni ValbusaBracco Imaging S.p.A., Via Egidio Folli 50, 20134, Milan, Italy.
Francesca RigiroliUniversità degli Studi di Milano, Scuola di specializzazione di Radiodiagnostica, Via Festa del Perdono 7, Milan, Italy.
Bernardo ColomboUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy.
Massimo BuscemaCentro Ricerche Semeion, Via Sersale 117, 00128, Rome, Italy.
Deborah FazziniUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy.
Marco AliUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy.
Ala MalasevschiUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy.
Gianpaolo CornalbaUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy.
Sergio PapaUnit of Diagnostic Imaging and Stereotactic Radiotherapy, Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferentiate malignant from benign enhancing foci on breast magnetic resonance imaging (MRI) through radiomic signature.

methodsForty-five enhancing foci in 45 patients were included in this retrospective study, with needle biopsy or imaging follow-up serving as a reference standard. There were 12 malignant and 33 benign lesions. Eight benign lesions confirmed by over 5-year negative follow-up and 15 malignant histopathologically confirmed lesions were added to the dataset to provide reference cases to the machine learning analysis. All MRI examinations were performed with a 1.5-T scanner. One three-dimensional T1-weighted unenhanced sequence was acquired, followed by four dynamic sequences after intravenous injection of 0.1 mmol/kg of gadobenate dimeglumine. Enhancing foci were segmented by an expert breast radiologist, over 200 radiomic features were extracted, and an evolutionary machine learning method ("training with input selection and testing") was applied. For each classifier, sensitivity, specificity and accuracy were calculated as point estimates and 95% confidence intervals (CIs).

resultsA k-nearest neighbour classifier based on 35 selected features was identified as the best performing machine learning approach. Considering both the 45 enhancing foci and the 23 additional cases, this classifier showed a sensitivity of 27/27 (100%, 95% CI 87-100%), a specificity of 37/41 (90%, 95% CI 77-97%), and an accuracy of 64/68 (94%, 95% CI 86-98%).

conclusionThis preliminary study showed the feasibility of a radiomic approach for the characterisation of enhancing foci on breast MRI.

Indexed as

Machine LearningAdultBreast NeoplasmsContrast MediaDiagnosis, DifferentialFeasibility StudiesFemaleHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMeglumineMiddle AgedOrganometallic CompoundsRetrospective StudiesContrast Mediagadobenic acidMeglumineOrganometallic CompoundsArtificial intelligenceBreast neoplasmsGadobenic acidMachine learningMagnetic resonance imaging

Identifiers

PMID31993839
PMCPMC6987284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.